Effects of Sodium–Glucose Cotransporter 2 Inhibitor Use on Mortality, Amputation, and Healing in Patients With Diabetic Foot Ulcer
Authors' conclusion
The use of SGLT2is does not negatively impact the 1-year amputation rate or healing rate of DFU. One-year mortality was lower in patients treated with an SGLT2i.
Study context
- Population
- Patients treated for a new diabetic foot ulcer (DFU) between January 2022 and May 2024 with 1 year of follow-up, French specialized diabetic foot center; mean ± SD age 70.2 ± 11.6 years, 77% men
- Participants
- 452 patients
- Exposure
- SGLT2i use vs no SGLT2i use
- SGLT2in = 94
- No SGLT2in = 358reference
- Outcome
- Amputation rate
- Follow-up
- 1 year
Methodological detailsmonocentric, specialized diabetic foot center
- Monocentric
- Specialized diabetic foot center
Main finding
As reported in the abstract
- SGLT2i vs No SGLT2i: P = 0.688
- Adjusted statistical model
Observational data: associations, not effects.
Further findings
Healing rate · 6 months · not significantly different
P = 0.091
| Outcome | Mean ± SD difference (days) | P value |
|---|---|---|
| Healing timeShorter with SGLT2i | 44 | P = 0.04 |
- Mortality · 1 year · significantly lower with SGLT2i
- P = 0.009
Original publication
Effects of Sodium–Glucose Cotransporter 2 Inhibitor Use on Mortality, Amputation, and Healing in Patients With Diabetic Foot Ulcer. Diabetes Care. Published 25 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →